Skip to main content
Premium Trial:

Request an Annual Quote

Genomics One Private Placement Delayed as New Terms Discussed with Investors

NEW YORK, July 4 (GenomeWeb News) - Genomics One said last week that a $500,000 private placement, announced on June 3, has not been concluded under the timeline and terms prescribed by the TSX Ventures Exchange.


The placement was to support the company's biodefense operations.


Genomics One said that it is currently negotiating new terms for the placement with its potential investors. The new terms are subject to TSX Ventures Exchange approval.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.